ESSA Pharma Inc. (EPIX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have earned a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company. ESSA Pharma’s rating score has declined by 67% in the last three months as a result of a number of analysts’ ratings changes.

Brokers have set a one year consensus price target of $5.10 for the company and are predicting that the company will post ($0.18) EPS for the current quarter, according to Zacks. Zacks has also given ESSA Pharma an industry rank of 163 out of 265 based on the ratings given to related companies.

Several research analysts have recently commented on EPIX shares. Zacks Investment Research raised ESSA Pharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Bloom Burton lowered ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Finally, Dawson James reissued a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd.

ESSA Pharma (NASDAQ:EPIX) traded up 0.380% during midday trading on Friday, hitting $0.264. The stock had a trading volume of 43,500 shares. The stock’s market cap is $7.68 million. ESSA Pharma has a 52-week low of $0.25 and a 52-week high of $3.59. The company’s 50 day moving average price is $0.29 and its 200-day moving average price is $0.29.

ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

What are top analysts saying about ESSA Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ESSA Pharma Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit